Xvivo Perfusion Ab Stock Market Value
| XVIPF Stock | USD 19.30 4.22 17.94% |
| Symbol | Xvivo |
Xvivo Perfusion 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Xvivo Perfusion's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Xvivo Perfusion.
| 11/27/2025 |
| 02/25/2026 |
If you would invest 0.00 in Xvivo Perfusion on November 27, 2025 and sell it all today you would earn a total of 0.00 from holding Xvivo Perfusion AB or generate 0.0% return on investment in Xvivo Perfusion over 90 days. Xvivo Perfusion is related to or competes with CSL, MERCK Kommanditgesells, Merck KGaA, Hoya Corp, Chugai Pharmaceutical, Chugai Pharmaceutical, and Lonza Group. Xvivo Perfusion AB , a medical technology company, develops solutions for organ, tissue, and cell preservation and perfu... More
Xvivo Perfusion Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Xvivo Perfusion's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Xvivo Perfusion AB upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.47 | |||
| Information Ratio | 0.0322 | |||
| Maximum Drawdown | 18.97 | |||
| Value At Risk | (2.08) | |||
| Potential Upside | 5.59 |
Xvivo Perfusion Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xvivo Perfusion's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Xvivo Perfusion's standard deviation. In reality, there are many statistical measures that can use Xvivo Perfusion historical prices to predict the future Xvivo Perfusion's volatility.| Risk Adjusted Performance | 0.0541 | |||
| Jensen Alpha | 0.2449 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.0156 | |||
| Treynor Ratio | (0.50) |
Xvivo Perfusion February 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0541 | |||
| Market Risk Adjusted Performance | (0.49) | |||
| Mean Deviation | 1.46 | |||
| Semi Deviation | 2.58 | |||
| Downside Deviation | 7.47 | |||
| Coefficient Of Variation | 1661.07 | |||
| Standard Deviation | 3.61 | |||
| Variance | 13.04 | |||
| Information Ratio | 0.0322 | |||
| Jensen Alpha | 0.2449 | |||
| Total Risk Alpha | (0.22) | |||
| Sortino Ratio | 0.0156 | |||
| Treynor Ratio | (0.50) | |||
| Maximum Drawdown | 18.97 | |||
| Value At Risk | (2.08) | |||
| Potential Upside | 5.59 | |||
| Downside Variance | 55.8 | |||
| Semi Variance | 6.63 | |||
| Expected Short fall | (6.23) | |||
| Skewness | (0.48) | |||
| Kurtosis | 13.93 |
Xvivo Perfusion AB Backtested Returns
At this point, Xvivo Perfusion is not too volatile. Xvivo Perfusion AB shows Sharpe Ratio of close to zero, which attests that the company had a close to zero % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Xvivo Perfusion AB, which you can use to evaluate the volatility of the company. Please check out Xvivo Perfusion's Market Risk Adjusted Performance of (0.49), mean deviation of 1.46, and Downside Deviation of 7.47 to validate if the risk estimate we provide is consistent with the expected return of 0.0249%. The firm maintains a market beta of -0.41, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Xvivo Perfusion are expected to decrease at a much lower rate. During the bear market, Xvivo Perfusion is likely to outperform the market. Xvivo Perfusion AB right now maintains a risk of 3.38%. Please check out Xvivo Perfusion AB treynor ratio, as well as the relationship between the semi variance and day median price , to decide if Xvivo Perfusion AB will be following its historical returns.
Auto-correlation | -0.1 |
Very weak reverse predictability
Xvivo Perfusion AB has very weak reverse predictability. Overlapping area represents the amount of predictability between Xvivo Perfusion time series from 27th of November 2025 to 11th of January 2026 and 11th of January 2026 to 25th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Xvivo Perfusion AB price movement. The serial correlation of -0.1 indicates that less than 10.0% of current Xvivo Perfusion price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.1 | |
| Spearman Rank Test | 0.18 | |
| Residual Average | 0.0 | |
| Price Variance | 2.56 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.